•Notícia
The research may contribute to the development of more effective drugs against malaria
The effectiveness of a new drug against malaria has been proved using synchrotron light
Researchers from the Universitat Politècnica de Catalunya · BarcelonaTech (UPC), the Instituto de Química Mèdica (IQM-CSIC) and the University of Glasgow have proved that the CD27 drug is a true alternative against malaria. They have analysed the crystalline structure of the DNA with the drug by performing X-ray diffraction experiments at the ALBA synchrotron.
21/07/2014
href="https://saladepremsa2.upc.edu/en"href="https://saladepremsa2.upc.edu/en"href="https://saladepremsa2.upc.edu/en"">ALBA synchrotron. X-rays, when they pass through the crystal and diffract, project images of spots which, after mathematic analysis, can solve the tridimensional structure of a molecule. When MACROM researchers solved the 3D structure, they identified the details of CD27’s structure, enabling the drug to recognise the regions of DNA covering the minor groove and preventing the development of the parasite. At the same time, these studies contribute to a rational design of new drugs, bearing in mind the molecular interactions caused by CD27.
Results of this research have been validated and deposited at the Protein Data Bank, a 3D database of proteins and nucleic acids, and published in the journal Acta Crystallographica D. The drug is patent-free and can be produced by any pharmaceutical company interested in its development.
This scientific infrastructure produces 5,000 hours of beamtime per year and is available for academics and the industrial sector and serves more than 1,000 researchers every year.
Results of this research have been validated and deposited at the Protein Data Bank, a 3D database of proteins and nucleic acids, and published in the journal Acta Crystallographica D. The drug is patent-free and can be produced by any pharmaceutical company interested in its development.
Malaria, responsible for more than one million deaths every year
Malaria is an infectious disease caused by a parasite of the Plasmodium genus that is transmitted by a mosquito bite. It deeply affects African countries, although it is also present in some areas of Latin America and Asia (with an estimated at-risk population of 3.4 billion, according to the World Health Organization). It is thought that malaria causes more than one million deaths every year and the parasite’s resistance to existing drugs is an obstacle in the treatment of the disease.The ALBA synchrotron
ALBA is the Spanish synchrotron light source. It is a complex of electron accelerators that produce synchrotron light, which allows the atomic structure of matter to be visualised and its properties to be studied. ALBA has been in operation since May 2012 and has seven experimental beamlines. This scientific infrastructure produces 5,000 hours of beamtime per year and is available for academics and the industrial sector and serves more than 1,000 researchers every year.
Reference: “In and out of the minor groove: interaction of an AT-rich DNA with the drug CD27” [pdf] Francisco J. Acosta-Reyes, Christophe Dardonville, Harry P. De Koning, Manal Natto, Juan A. Subirana and J. Lourdes Campos. Acta Crystallographica Section D Biological Crystallography 70 1614-1621
Segueix-nos a Twitter